VA-MENGOC-BC® 疫苗诱导的交叉保护作用。
Cross-protection induced by VA-MENGOC-BC® vaccine.
机构信息
a Department of Immunology , Institute of Basic and Preclinical Sciences, University of Medical Sciences, Senior Researcher at the Finlay Institute of Vaccines , Havana , Cuba.
出版信息
Hum Vaccin Immunother. 2018 May 4;14(5):1064-1068. doi: 10.1080/21645515.2018.1438028. Epub 2018 Feb 26.
Abstract
I would like to comment on the article "Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief", DOI: 10.1080/21645515.2017.1381810. The author states that meningococcal group B OMVs vaccines -such as VA-MENGOC-BC®- may induce moderate protection against Neisseria gonorrhoeae. I agree. However, the author states that "there was no evidence of effectiveness in the younger children." The effectiveness of VA-MENGOC-BC® in heterologous contexts has been higher than 80% in individuals older than 4 years old, but the effectiveness in younger children should not be undervalued; it has usually been higher than 60%, and results markedly higher when evaluated based on mortality rates. There is strong evidence that VA-MENGOC-BC® may induce cross-protection against heterologous N. meningitidis strains and N. gonorrhoeae.
摘要
我想对文章“评论：脑膜炎奈瑟菌 B 型 OMV 疫苗的影响，超出其短暂性”，DOI：10.1080/21645515.2017.1381810. 进行评论。作者指出，脑膜炎奈瑟菌 B 型 OMV 疫苗 - 如 VA-MENGOC-BC® - 可能对淋病奈瑟菌产生适度的保护作用。我同意这一观点。然而，作者指出，“在年幼的儿童中没有证据表明其有效性。”VA-MENGOC-BC®在异源环境中的有效性在 4 岁以上的个体中高于 80%，但不应低估其在年幼儿童中的有效性；其有效性通常高于 60%，当根据死亡率进行评估时，结果明显更高。有强有力的证据表明，VA-MENGOC-BC®可能诱导针对异源脑膜炎奈瑟菌菌株和淋病奈瑟菌的交叉保护作用。
相似文献
1
Cross-protection induced by VA-MENGOC-BC® vaccine.VA-MENGOC-BC® 疫苗诱导的交叉保护作用。
Hum Vaccin Immunother. 2018 May 4;14(5):1064-1068. doi: 10.1080/21645515.2018.1438028. Epub 2018 Feb 26.
2
Impact of meningococcal group B OMV vaccines, beyond their brief.脑膜炎 B 型寡糖结合疫苗的影响，超出其预期。
Hum Vaccin Immunother. 2018 May 4;14(5):1058-1063. doi: 10.1080/21645515.2017.1381810. Epub 2017 Nov 17.
3
Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.古巴A群脑膜炎球菌结合疫苗VA-MENGOC-BC：30年的使用历程与未来潜力
MEDICC Rev. 2019 Oct;21(4):19-27. doi: 10.37757/MR2019.V21.N4.4.
4
VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.VA-MENGOC-BC 疫苗接种可诱导血清和黏膜抗淋病奈瑟菌免疫应答，并降低淋病发病率。
Pediatr Infect Dis J. 2021 Apr 1;40(4):375-381. doi: 10.1097/INF.0000000000003047.
5
A meningococcal B vaccine induces cross-protection against gonorrhea.一种B型脑膜炎球菌疫苗可诱导对淋病的交叉保护作用。
Clin Exp Vaccine Res. 2019 Jul;8(2):110-115. doi: 10.7774/cevr.2019.8.2.110. Epub 2019 Jul 31.
6
7
Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.脑膜炎球菌疫苗对淋病感染的疫苗效力及影响：一项系统评价与荟萃分析。
J Infect. 2024 Sep;89(3):106225. doi: 10.1016/j.jinf.2024.106225. Epub 2024 Jul 8.
8
A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.更深入地挖掘 VA-MENGOC-BC® 疫苗的蛋白组成：一种针对 B 群和 C 群脑膜炎奈瑟菌的 OMV 疫苗。
Hum Vaccin Immunother. 2017 Nov 2;13(11):2548-2560. doi: 10.1080/21645515.2017.1356961. Epub 2017 Oct 30.
9
Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.从巴西流行的B群脑膜炎奈瑟菌菌株中获得的外膜囊泡（OMV）和解毒脂寡糖（dLOS）可保护小鼠免受同源和异源脑膜炎球菌感染及败血性休克。
Vaccine. 2004 Jun 30;22(20):2617-25. doi: 10.1016/j.vaccine.2003.12.009.
10
Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.针对B群脑膜炎奈瑟菌的VA-MENGOC-BC疫苗的外膜囊泡：通过二维凝胶电泳和质谱分析蛋白质成分
Proteomics. 2006 Jun;6(11):3389-99. doi: 10.1002/pmic.200500502.
引用本文的文献
1
A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.一种新型的基于颗粒性脑膜炎球菌疫苗（GMMA）的淋球菌疫苗在小鼠中显示出功能性免疫反应。
NPJ Vaccines. 2025 Jul 5;10(1):146. doi: 10.1038/s41541-025-01190-1.
2
Isolation of Extracellular Outer Membrane Vesicles (OMVs) from Using EVscore47 Beads.使用EVscore47磁珠从[具体来源未给出]中分离细胞外外膜囊泡（OMV） 。
Molecules. 2024 Apr 17;29(8):1831. doi: 10.3390/molecules29081831.
3
Evaluating vaccine-elicited antibody activities against : cross-protective responses elicited by the 4CMenB meningococcal vaccine.评估疫苗诱导的抗体活性针对：4CMenB 脑膜炎球菌疫苗诱导的交叉保护反应。
Infect Immun. 2023 Dec 12;91(12):e0030923. doi: 10.1128/iai.00309-23. Epub 2023 Nov 22.
4
Immune responses to and implications for vaccine development.针对 的免疫反应及其对疫苗开发的意义。
Front Immunol. 2023 Aug 17;14:1248613. doi: 10.3389/fimmu.2023.1248613. eCollection 2023.
5
Preventing invasive meningococcal disease in early infancy.预防婴幼儿侵袭性脑膜炎球菌病。
Hum Vaccin Immunother. 2022 Nov 30;18(5):1979846. doi: 10.1080/21645515.2021.1979846. Epub 2022 Apr 28.
6
Recent Progress Towards a Gonococcal Vaccine.淋球菌疫苗的最新研究进展
Front Cell Infect Microbiol. 2022 Apr 11;12:881392. doi: 10.3389/fcimb.2022.881392. eCollection 2022.
7
An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol.一项评估4CMenB对澳大利亚北领地青少年脑膜炎球菌病、带菌状态及淋病有效性的观察性研究——研究方案
Vaccines (Basel). 2022 Feb 16;10(2):309. doi: 10.3390/vaccines10020309.
8
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.一项关于两种重组二聚体 RBD COVID-19 疫苗候选物的随机、双盲 I 期临床试验：安全性、反应原性和免疫原性。
Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8.
9
Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.用于控制和预防性传播疾病淋病的候选疫苗
Vaccines (Basel). 2021 Jul 20;9(7):804. doi: 10.3390/vaccines9070804.
10
Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.评价 4CMenB 疫苗在婴幼儿和青少年计划中预防侵袭性脑膜炎球菌病和淋病的效果：方案。
Hum Vaccin Immunother. 2021 May 4;17(5):1450-1454. doi: 10.1080/21645515.2020.1827614. Epub 2021 Jan 11.
本文引用的文献
1
Impact of meningococcal group B OMV vaccines, beyond their brief.脑膜炎 B 型寡糖结合疫苗的影响，超出其预期。
Hum Vaccin Immunother. 2018 May 4;14(5):1058-1063. doi: 10.1080/21645515.2017.1381810. Epub 2017 Nov 17.
2
Meningococcal serogroup B vaccines: Estimating breadth of coverage.B型脑膜炎球菌疫苗：覆盖范围评估
Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14.
3
A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.一项III期观察者盲法随机对照研究，旨在评估大学生接种四价ACWY脑膜炎球菌糖共轭疫苗或B群脑膜炎球菌疫苗后的免疫反应及其与鼻咽部带菌情况的相关性。
Vaccine. 2017 Jan 11;35(3):427-434. doi: 10.1016/j.vaccine.2016.11.071. Epub 2016 Nov 29.
4
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.一种B群脑膜炎球菌疫苗在大学疫情期间的免疫原性
N Engl J Med. 2016 Jul 21;375(3):220-8. doi: 10.1056/NEJMoa1514866.
5
Meningococcal B vaccine and the vision of a meningitis free world.B 型脑膜炎球菌疫苗与无脑膜炎世界的愿景
J Prev Med Hyg. 2015 Aug 31;56(3):E140-3.
6
Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.脑膜炎球菌病暴发的预防与控制：B 群脑膜炎球菌疫苗的新作用
Vaccine. 2015 Jul 17;33(31):3628-35. doi: 10.1016/j.vaccine.2015.06.046. Epub 2015 Jun 17.
7
Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.免疫蛋白质组学分析人类对实验性脑膜炎奈瑟菌外膜囊泡疫苗的免疫反应，鉴定潜在的交叉反应性抗原。
Vaccine. 2014 Mar 5;32(11):1280-6. doi: 10.1016/j.vaccine.2013.12.070. Epub 2014 Jan 30.
8
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.因子 H 结合蛋白在脑膜炎奈瑟菌毒力中的作用及其作为广泛预防脑膜炎球菌病疫苗候选物的潜力。
Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12.
9
[Effectiveness of the anti-meningococcal vaccine VA-MENGO-BC in the first year of life of Cuban children, 1997-2008].[抗脑膜炎球菌疫苗VA-MENGO-BC在1997 - 2008年古巴儿童出生第一年的有效性]
Rev Cubana Med Trop. 2011 May-Aug;63(2):155-60.
10
[Characterization of Neisseria meningitidis strains isolated from carriers in Cuba during 20 years].[古巴20年间从携带者中分离出的脑膜炎奈瑟菌菌株的特征分析]
Rev Cubana Med Trop. 2006 May-Aug;58(2):124-33.
Zotero 插件